{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:31:50Z","timestamp":1789432310815,"version":"build-2803163510"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T00:00:00Z","timestamp":1558742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T00:00:00Z","timestamp":1558742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Model"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00894-019-4032-5","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T03:02:41Z","timestamp":1558753361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3\u03b2 inhibitors"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4127-9055","authenticated-orcid":false,"given":"Ahmed M.","family":"El Kerdawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa A.","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa A.","family":"Zaater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,25]]},"reference":[{"key":"4032_CR1","unstructured":"Katzman R (1988) Alzheimer\u2019s disease as an age-dependent disorder. Res Age Pop 134:69\u201385"},{"key":"4032_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev.neuro.26.043002.094919","volume":"26","author":"R Mayeux","year":"2003","unstructured":"Mayeux R (2003) Epidemiology of neurodegeneration. Annu Rev Neurosci 26:81\u2013104. https:\/\/doi.org\/10.1146\/annurev.neuro.26.043002.094919","journal-title":"Annu Rev Neurosci"},{"key":"4032_CR3","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S0896-6273(00)80115-4","volume":"16","author":"BA Yankner","year":"1996","unstructured":"Yankner BA (1996) Mechanisms of neuronal degeneration in Alzheimer\u2019s disease. Neuron 16:921\u2013932. https:\/\/doi.org\/10.1016\/S0896-6273(00)80115-4","journal-title":"Neuron"},{"key":"4032_CR4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/archneur.1985.04060100083029","volume":"42","author":"ZS Khachaturian","year":"1985","unstructured":"Khachaturian ZS (1985) Diagnosis of Alzheimer\u2019s disease. Arch Neurol 42:1097\u20131105","journal-title":"Arch Neurol"},{"key":"4032_CR5","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1469-1809.1959.tb01473.x","volume":"23","author":"BYL Wheelan","year":"1959","unstructured":"Wheelan BYL (1959) Familial Alzheimer \u2019 s D I S E A S E. Annu Hum Genet 23:300\u2013310","journal-title":"Annu Hum Genet"},{"key":"4032_CR6","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","volume":"2","author":"P Davies","year":"1976","unstructured":"Davies P, Maloney AJF (1976) Selective loss of central cholinergic neurons in Alzheimer\u2019S disease. Lancet 2:1403. https:\/\/doi.org\/10.1016\/S0140-6736(76)91936-X","journal-title":"Lancet"},{"key":"4032_CR7","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/0006-291X(84)91209-9","volume":"122","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW (1984) Alheimer\u2019s disease and Down\u2019s syndrome sharing a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122:1131\u20131135","journal-title":"Biochem Biophys Res Commun"},{"key":"4032_CR8","doi-asserted-by":"publisher","unstructured":"Zlokovic B V (2014) Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders. Nat Rev Neurosci 12:723\u2013738. https:\/\/doi.org\/10.1038\/nrn3114.Neurovascular","DOI":"10.1038\/nrn3114.Neurovascular"},{"key":"4032_CR9","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/00005072-199409000-00003","volume":"53","author":"D Selekoe","year":"1994","unstructured":"Selekoe D (1994) Alzheimer\u2019s disease: a central role for amyloid. J Neuropathol Exp Neurol 53:438\u2013447","journal-title":"J Neuropathol Exp Neurol"},{"key":"4032_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nrd1415","volume":"3","author":"P Cohen","year":"2004","unstructured":"Cohen P, Goedert M (2004) Gsk3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3:479\u2013487. https:\/\/doi.org\/10.1038\/nrd1415","journal-title":"Nat Rev Drug Discov"},{"key":"4032_CR11","doi-asserted-by":"crossref","first-page":"17082","DOI":"10.1016\/S0021-9258(18)41896-0","volume":"267","author":"H Mori","year":"1992","unstructured":"Mori H, Takio K, Ogawarag M, Selkoe DJ (1992) Mass spectrometry of purified amyloid \u03b2 protein in Alzheimer\u2019s disease. J Biol Chem 267:17082\u201317086","journal-title":"J Biol Chem"},{"key":"4032_CR12","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/0092-8674(93)90635-4","volume":"73","author":"JT Jerrett","year":"1993","unstructured":"Jerrett JT, Lansbury PT (1993) Seeding one-dimensional crystallization of amyloid\u00a0: a pathogenic mechanism in Alzheimer\u2019 s disease and scrapie\u00a0? Cell 73:1055\u20131058","journal-title":"Cell"},{"key":"4032_CR13","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.neuron.2008.11.007","volume":"60","author":"SA Small","year":"2008","unstructured":"Small SA, Duff K (2008) Perspective linking A\u03b2 and tau in late-onset Alzheimer\u2019s disease\u00a0: a dual pathway hypothesis. Cell Press Neuron Prespect 60:534\u2013542. https:\/\/doi.org\/10.1016\/j.neuron.2008.11.007","journal-title":"Cell Press Neuron Prespect"},{"key":"4032_CR14","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1242\/jcs.01018","volume":"117","author":"Y Tatebayashi","year":"2004","unstructured":"Tatebayashi Y, Haque N, Tung Y et al (2004) Role of tau phosphorylation by glycogen synthase kinase-3 \u03b2 in the regulation of organelle transport. J Cell Sci 117:1653\u20131663. https:\/\/doi.org\/10.1242\/jcs.01018","journal-title":"J Cell Sci"},{"key":"4032_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1083\/jcb.143.3.777","volume":"143","author":"A Ebneth","year":"1998","unstructured":"Ebneth A, Godemann R, Stamer K et al (1998) Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer\u2019s disease. J Cell Biol 143:777\u2013794","journal-title":"J Cell Biol"},{"key":"4032_CR16","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1083\/jcb.103.6.2739","volume":"103","author":"DG Drubin","year":"1986","unstructured":"Drubin DG, Kirschner MW (1986) Tau protein function in living cells. J Cell Biol 103:2739\u20132746","journal-title":"J Cell Biol"},{"key":"4032_CR17","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1073\/pnas.72.5.1858","volume":"72","author":"MD Weingarten","year":"1975","unstructured":"Weingarten MD, Lockwood AH, Hwo S, Kirschner MW (1975) A protein factor essential for microtubule assembly (tau factor\/tubulin\/electron microscopy\/phosphocellulose) MURRAY. Proc Natl Acad Sci 72:1858\u20131862","journal-title":"Proc Natl Acad Sci"},{"key":"4032_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1083\/jcb.131.5.1327","volume":"131","author":"R Brandt","year":"1995","unstructured":"Brandt R, Leger J, Lee G (1995) Interaction of tau with the neural plasma membrane mediated by tau \u2019 s amino-terminal projection domain. J Cell Biol 131:1327\u20131340","journal-title":"J Cell Biol"},{"key":"4032_CR19","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"MP Lambert","year":"1998","unstructured":"Lambert MP, Barlow AK, Chromy BA et al (1998) Diffusible, nonfibrillar ligands derived from A\u03b2 1\u201342 are potent central nervous system neurotoxins. Proc Natl Acad Sci 95:6448\u20136453","journal-title":"Proc Natl Acad Sci"},{"key":"4032_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cell.2005.02.008","volume":"120","author":"RE Tanzi","year":"2005","unstructured":"Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer\u2019s disease amyloid hypothesis\u00a0: a genetic perspective. Cell 120:545\u2013555. https:\/\/doi.org\/10.1016\/j.cell.2005.02.008","journal-title":"Cell"},{"key":"4032_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1083\/jcb.200110119","volume":"156","author":"Y Zhang","year":"2002","unstructured":"Zhang Y, Mclaughlin R, Goodyer C, Leblanc A (2002) Selective cytotoxicity of intracellular amyloid \u03b2 peptide 1\u201342 through p53 and Bax in cultured primary human neurons. J Cell Biol 156:519\u2013529. https:\/\/doi.org\/10.1083\/jcb.200110119","journal-title":"J Cell Biol"},{"key":"4032_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer\u2019 s disease\u00a0: Progress and problems on the road to therapeutics. Sci compass 297:353\u2013356. https:\/\/doi.org\/10.1126\/science.1072994","journal-title":"Sci compass"},{"key":"4032_CR23","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S1097-2765(01)00253-2","volume":"7","author":"S Frame","year":"2001","unstructured":"Frame S, Cohen P, Biondi RM (2001) A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7:1321\u20131327","journal-title":"Mol. Cell"},{"key":"4032_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1074\/jbc.M206236200","volume":"278","author":"J Cho","year":"2003","unstructured":"Cho J, Johnson GVW (2003) Glycogen synthase kinase 3\u03b2 phosphorylates tau at both primed and unprimed sites. J Biol Chem 278:187\u2013193. https:\/\/doi.org\/10.1074\/jbc.M206236200","journal-title":"J Biol Chem"},{"key":"4032_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1152\/physrev.00024.2003","volume":"84","author":"S Avila","year":"2004","unstructured":"Avila S, Lucas J, PEREZ M, Hernandez F (2004) Role of tau protein in both physiological and pathological conditions. Physiol Rev 84:361\u2013384","journal-title":"Physiol Rev"},{"key":"4032_CR26","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1046\/j.1471-4159.2002.01269.x","volume":"83","author":"F Hernandez","year":"2002","unstructured":"Hernandez F, Borrell J, Guaza C et al (2002) Spatial learning deficit in transgenic mice that conditionally over-express GSK-3\u03b2 in the brain but do not form tau filaments. J Neurochem 83:1529\u20131533","journal-title":"J Neurochem"},{"key":"4032_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1042\/bj2940625","volume":"294","author":"GI Welsh","year":"1993","unstructured":"Welsh GI, Proud CG (1993) Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem J 294:625\u2013629. https:\/\/doi.org\/10.1042\/bj2940625","journal-title":"Biochem J"},{"key":"4032_CR28","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","volume":"104","author":"C Hooper","year":"2008","unstructured":"Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer\u2019s disease. J Neurochem 104:1433\u20131439. https:\/\/doi.org\/10.1111\/j.1471-4159.2007.05194.x","journal-title":"J Neurochem"},{"key":"4032_CR29","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/j.1471-4159.2004.02422.x","volume":"89","author":"RV Bhat","year":"2004","unstructured":"Bhat RV, Budd Haeberlein SL, Avila J (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89:1313\u20131317. https:\/\/doi.org\/10.1111\/j.1471-4159.2004.02422.x","journal-title":"J Neurochem"},{"key":"4032_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/j.1460-2075.1993.tb05715.x","volume":"12","author":"K Hughes","year":"1993","unstructured":"Hughes K, Nikolakaki E, Plyte SE et al (1993) Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 12:803\u2013808. https:\/\/doi.org\/10.1002\/j.1460-2075.1993.tb05715.x","journal-title":"EMBO J."},{"key":"4032_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/med.10011","volume":"22","author":"A Martinez","year":"2002","unstructured":"Martinez A, Castro A, Dorronsoro I, Alonso M (2002) Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 22:373\u2013384. https:\/\/doi.org\/10.1002\/med.10011","journal-title":"Med Res Rev"},{"key":"4032_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1155\/2012\/578373","volume":"586","author":"J Avila","year":"2012","unstructured":"Avila J, Le\u00f3n-Espinosa G, Garc\u00eda E et al (2012) Tau phosphorylation by GSK3 in different conditions. FEBS Lett 586:47\u201354. https:\/\/doi.org\/10.1155\/2012\/578373","journal-title":"FEBS Lett."},{"key":"4032_CR33","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1242\/jcs.00384","volume":"116","author":"BW Doble","year":"2003","unstructured":"Doble BW, Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116:1175\u20131186. https:\/\/doi.org\/10.1242\/jcs.00384","journal-title":"J Cell Sci"},{"key":"4032_CR34","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ejmech.2018.12.073","volume":"164","author":"M Xu","year":"2019","unstructured":"Xu M, Wang SL, Zhu L et al (2019) Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3\u03b2 inhibitors: a critical review M. Eur J Med Chem 164:448\u2013470. https:\/\/doi.org\/10.1016\/j.ejmech.2018.12.073","journal-title":"Eur J Med Chem"},{"key":"4032_CR35","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ijthermalsci.2011.11.008","volume":"57","author":"OPJ Van Linden","year":"2013","unstructured":"Van Linden OPJ, Kooistra AJ, Leurs R et al (2013) KLIFS: knowledge-based structural database to navigate kinase-ligand interaction space. J Med Chem 57:249\u2013277. https:\/\/doi.org\/10.1016\/j.ijthermalsci.2011.11.008","journal-title":"J Med Chem"},{"key":"4032_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1021\/jm0608107","volume":"50","author":"JJ-L Liao","year":"2007","unstructured":"Liao JJ-L (2007) Molecular recognition of protein kinase binding pockets for Design of Potent and Selective Kinase Inhibitors. J Med Chem 50:409\u2013424","journal-title":"J Med Chem"},{"key":"4032_CR37","doi-asserted-by":"publisher","first-page":"D365","DOI":"10.1093\/nar\/gkv1082","volume":"44","author":"AJ Kooistra","year":"2016","unstructured":"Kooistra AJ, Kanev GK, Van Linden OPJ et al (2016) KLIFS: a structural kinase-ligand interaction database. Nucleic Acids Res 44:D365\u2013D371. https:\/\/doi.org\/10.1093\/nar\/gkv1082","journal-title":"Nucleic Acids Res."},{"key":"4032_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejmech.2018.11.061","volume":"163","author":"WM Eldehna","year":"2019","unstructured":"Eldehna WM, El Kerdawy AM, Al-Ansary GH et al (2019) Type IIA - type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. Eur J Med Chem 163:37\u201353. https:\/\/doi.org\/10.1016\/j.ejmech.2018.11.061","journal-title":"Eur J Med Chem"},{"key":"4032_CR39","doi-asserted-by":"publisher","first-page":"9107","DOI":"10.1021\/jm201724m","volume":"55","author":"S Berg","year":"2012","unstructured":"Berg S, Bergh M, Hellberg S et al (2012) Discovery of novel potent and highly selective glycogen synthase kinase-3\u03b2 (GSK3\u03b2) inhibitors for Alzheimer\u2019s disease: design, synthesis, and characterization of pyrazines. J Med Chem 55:9107\u20139119. https:\/\/doi.org\/10.1021\/jm201724m","journal-title":"J Med Chem"},{"key":"4032_CR40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jmb.2003.08.031","volume":"333","author":"JA Bertrand","year":"2003","unstructured":"Bertrand JA, Thieffine S, Vulpetti A et al (2003) Structural characterization of the GSK-3\u03b2 active site using selective and non-selective ATP-mimetic inhibitors. J Mol Biol 333:393\u2013407. https:\/\/doi.org\/10.1016\/j.jmb.2003.08.031","journal-title":"J Mol Biol"},{"key":"4032_CR41","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.bmcl.2010.01.072","volume":"20","author":"M Arnost","year":"2010","unstructured":"Arnost M, Pierce A, ter HE et al (2010) 3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: highly ligand efficient and potent inhibitors of GSK3\u03b2. Bioorganic Med Chem Lett 20:1661\u20131664. https:\/\/doi.org\/10.1016\/j.bmcl.2010.01.072","journal-title":"Bioorganic Med Chem Lett"},{"key":"4032_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-642-66626-1_4","volume-title":"Progress in Molecular and Subcellular Biology","author":"Peter Gund","year":"1977","unstructured":"Gund P (1977) Three-dimensional pharmacophoric pattern searching. In: Progress in molecular and subcellular biology, vol 5. Springer, Berlin, pp 117\u2013143"},{"key":"4032_CR43","doi-asserted-by":"publisher","first-page":"22799","DOI":"10.3390\/molecules201219880","volume":"20","author":"T Kaserer","year":"2015","unstructured":"Kaserer T, Beck KR, Akram M et al (2015) Pharmacophore models and pharmacophore-based virtual screening: concepts and applications exemplified on hydroxysteroid dehydrogenases. Molecules 20:22799\u201322832","journal-title":"Molecules"},{"key":"4032_CR44","first-page":"261","volume-title":"Methods in Molecular Biology","author":"Dragos Horvath","year":"2010","unstructured":"Horvath D (2010) Pharmacophore-based virtual screening. In: Chemoinformatics and computational chemical biology. Methods in molecular biology (methods and protocols), vol 672. Humana Press, Totowa, pp 261\u2013298"},{"key":"4032_CR45","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1021\/ci800105p","volume":"48","author":"C Tintori","year":"2008","unstructured":"Tintori C, Corradi V, Magnani M et al (2008) Targets looking for drugs: a multistep computational protocol for the development of structure-based pharmacophores and their applications for hit discovery. J Chem Inf Model 48:2166\u20132179. https:\/\/doi.org\/10.1021\/ci800105p","journal-title":"J Chem Inf Model"},{"key":"4032_CR46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1023\/A:1008094712424","volume":"11","author":"CW Murray","year":"1997","unstructured":"Murray CW, Clark DE, Auton TR et al (1997) PRO_SELECT: combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology. J Comput Aided Mol Des 11:193\u2013207. https:\/\/doi.org\/10.1023\/A:1008094712424","journal-title":"J Comput Aided Mol Des"},{"key":"4032_CR47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF00126441","volume":"7","author":"V Gillet","year":"1993","unstructured":"Gillet V, Johnson AP, Mata P et al (1993) SPROUT: a program for structure generation. J Comput Aided Mol Des 7:127\u2013153. https:\/\/doi.org\/10.1007\/BF00126441","journal-title":"J Comput Aided Mol Des"},{"key":"4032_CR48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/BF00124387","volume":"6","author":"HJ B\u00f6hm","year":"1992","unstructured":"B\u00f6hm HJ (1992) The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des 6:61\u201378. https:\/\/doi.org\/10.1007\/BF00124387","journal-title":"J Comput Aided Mol Des"},{"issue":"12","key":"4032_CR49","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1021\/ja068256d","volume":"129","author":"Anna L. Bowman","year":"2007","unstructured":"Bowman AL, Lerner MG, Carlson HA (2007) Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system. J Am Chem Soc 129:3634\u20133640. https:\/\/doi.org\/10.1021\/ja068256d","journal-title":"Journal of the American Chemical Society"},{"key":"4032_CR50","doi-asserted-by":"crossref","unstructured":"Dixon SL (2010) Pharmacophore methods. Drug design: structure- and ligand-based approaches. Cambridge University Press, Cambridge, pp 137\u2013150","DOI":"10.1017\/CBO9780511730412.011"},{"key":"4032_CR51","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymeth.2014.10.013","volume":"71","author":"A Vuorinen","year":"2015","unstructured":"Vuorinen A, Schuster D (2015) Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling. Methods 71:113\u2013134. https:\/\/doi.org\/10.1016\/j.ymeth.2014.10.013","journal-title":"Methods"},{"key":"4032_CR52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1201\/b18799-7","volume-title":"In Silico Drug Discovery and Design","author":"Muhammad Akram","year":"2015","unstructured":"Akram M, Kaserer T, Shuster D (2015) Pharmacophore modeling and pharmacophore-based visual screening. In: Cavasotto CN (ed) In silico drug discovery and design: theory, methods, challenges, and applications. CRC, Boca Raton, pp 123\u2013153"},{"key":"4032_CR53","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/ci3001277","volume":"52","author":"JJ Irwin","year":"2012","unstructured":"Irwin JJ, Sterling T, Mysinger MM et al (2012) ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 52:1757\u20131768. https:\/\/doi.org\/10.1021\/ci3001277","journal-title":"J Chem Inf Model"},{"key":"4032_CR54","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen EF, Goddard TD, Huang CC et al (2004) UCSF chimera - a visualization system for exploratory research and analysis. J Comput Chem 25:1605\u20131612. https:\/\/doi.org\/10.1002\/jcc.20084","journal-title":"J Comput Chem"},{"key":"4032_CR55","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.bmcl.2011.01.017","volume":"21","author":"K Coffman","year":"2011","unstructured":"Coffman K, Brodney M, Cook J et al (2011) 6-Amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3\u03b2 inhibitors. Bioorganic Med Chem Lett 21:1429\u20131433. https:\/\/doi.org\/10.1016\/j.bmcl.2011.01.017","journal-title":"Bioorganic Med Chem Lett"},{"key":"4032_CR56","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/j.bmc.2009.01.019","volume":"17","author":"M Saitoh","year":"2009","unstructured":"Saitoh M, Kunitomo J, Kimura E et al (2009) Bioorganic & Medicinal Chemistry Design , synthesis and structure \u2013 activity relationships of 1 , 3 , 4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3b. Bioorg Med Chem 17:2017\u20132029. https:\/\/doi.org\/10.1016\/j.bmc.2009.01.019","journal-title":"Bioorg Med Chem"},{"key":"4032_CR57","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1021\/acs.jmedchem.5b01550","volume":"59","author":"G Luo","year":"2016","unstructured":"Luo G, Chen L, Burton CR et al (2016) Discovery of Isonicotinamides as highly selective , brain penetrable and orally active glycogen synthase Kinase-3 inhibitors discovery of Isonicotinamides as highly selective , brain penetrable and orally active glycogen synthase Kinase-3 inhibitors. J Med Chem 59:1041\u20131051. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01550","journal-title":"J Med Chem"},{"key":"4032_CR58","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1021\/acschembio.6b00306","volume":"11","author":"FF Wagner","year":"2016","unstructured":"Wagner FF, Bishop JA, Gale JP et al (2016) Inhibitors of glycogen synthase kinase 3 with exquisite kinome- wide selectivity and their functional effects. ASC Chem Biol 11:1952\u20131963. https:\/\/doi.org\/10.1021\/acschembio.6b00306","journal-title":"ASC Chem Biol"},{"key":"4032_CR59","doi-asserted-by":"publisher","first-page":"eaam8460","DOI":"10.1126\/scitranslmed.aam8460","volume":"10","author":"FF Wagner","year":"2018","unstructured":"Wagner FF, Benajiba L, Campbell AJ et al (2018) Exploiting an asp-Glu \u201c switch \u201d in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med 10:eaam8460","journal-title":"Sci Transl Med"},{"issue":"33","key":"4032_CR60","doi-asserted-by":"publisher","first-page":"9601","DOI":"10.1002\/anie.201603797","volume":"55","author":"Steven H. Liang","year":"2016","unstructured":"Liang SH, Chen JM, Normandin MD et al (2016) Discovery of a highly selective glycogen synthase Kinase-3 inhibitor (PF-04802367) that modulates tau phosphorylation in the brain: translation for PET neuroimaging. Angew Chemie Int Ed 55:9601\u20139605. https:\/\/doi.org\/10.1002\/anie.201603797","journal-title":"Angewandte Chemie International Edition"},{"key":"4032_CR61","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1021\/jm800977q","volume":"52","author":"M Menichincheri","year":"2008","unstructured":"Menichincheri M, Bargiotti A, Berthelsen J et al (2008) First Cdc7 kinase inhibitors: Pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem 52:293\u2013307. https:\/\/doi.org\/10.1021\/jm800977q","journal-title":"J Med Chem"},{"key":"4032_CR62","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1021\/acsmedchemlett.7b00296","volume":"8","author":"ZA Henley","year":"2017","unstructured":"Henley ZA, Bax BD, Inglesby LM et al (2017) From PIM1 to PI3K\u03b4 via GSK3\u03b2: target hopping through the Kinome. ACS Med Chem Lett 8:1093\u20131098. https:\/\/doi.org\/10.1021\/acsmedchemlett.7b00296","journal-title":"ACS Med Chem Lett"},{"issue":"31","key":"4032_CR63","doi-asserted-by":"publisher","first-page":"9970","DOI":"10.1002\/anie.201804917","volume":"57","author":"Roberta Tesch","year":"2018","unstructured":"Tesch R, Becker C, M\u00fcller MP et al (2018) An unusual intramolecular halogen bond guides conformational selection. Angew Chemie Int Ed 57:9970\u20139975. https:\/\/doi.org\/10.1002\/anie.201804917","journal-title":"Angewandte Chemie International Edition"},{"key":"4032_CR64","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1016\/j.bmcl.2015.05.085","volume":"25","author":"K Kumata","year":"2015","unstructured":"Kumata K, Yui J, Xie L et al (2015) Radiosynthesis and preliminary PET evaluation of glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) inhibitors containing [11C]methylsulfanyl, [11C]methylsulfinyl or [11C]methylsulfonyl groups. Bioorganic Med Chem Lett 25:3230\u20133233. https:\/\/doi.org\/10.1016\/j.bmcl.2015.05.085","journal-title":"Bioorganic Med Chem Lett"},{"key":"4032_CR65","doi-asserted-by":"publisher","first-page":"6270","DOI":"10.1021\/jm900647e","volume":"52","author":"M Saitoh","year":"2009","unstructured":"Saitoh M, Kunitomo J, Kimura E et al (2009) 2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3\u03b2 with good brain permeability. J Med Chem 52:6270\u20136286. https:\/\/doi.org\/10.1021\/jm900647e","journal-title":"J Med Chem"},{"key":"4032_CR66","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1021\/ml300348c","volume":"4","author":"Y Tong","year":"2013","unstructured":"Tong Y, Stewart KD, Florjancic AS et al (2013) Azaindole-based inhibitors of Cdc7 kinase: impact of the pre-DFG residue, Val 195. ACS Med Chem Lett 4:211\u2013215. https:\/\/doi.org\/10.1021\/ml300348c","journal-title":"ACS Med Chem Lett"},{"key":"4032_CR67","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.1016\/j.bmcl.2011.06.131","volume":"21","author":"MF Lo","year":"2011","unstructured":"Lo MF, Kramer T, Bol\u00e4nder A et al (2011) Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas. Bioorganic Med Chem Lett 21:5610\u20135615. https:\/\/doi.org\/10.1016\/j.bmcl.2011.06.131","journal-title":"Bioorganic Med Chem Lett"},{"key":"4032_CR68","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ejmech.2016.03.035","volume":"116","author":"V Sebasti\u00e1n","year":"2016","unstructured":"Sebasti\u00e1n V, Manoli MT, P\u00e9rez DI et al (2016) New applications for known drugs: human glycogen synthase kinase 3 inhibitors as modulators of Aspergillus fumigatus growth. Eur J Med Chem 116:281\u2013289. https:\/\/doi.org\/10.1016\/j.ejmech.2016.03.035","journal-title":"Eur J Med Chem"},{"key":"4032_CR69","doi-asserted-by":"publisher","first-page":"45937","DOI":"10.1074\/jbc.M306268200","volume":"278","author":"R Bhat","year":"2003","unstructured":"Bhat R, Xue Y, Berg S et al (2003) Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278:45937\u201345945. https:\/\/doi.org\/10.1074\/jbc.M306268200","journal-title":"J Biol Chem"},{"key":"4032_CR70","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1016\/j.bmc.2009.05.031","volume":"17","author":"Q Ye","year":"2009","unstructured":"Ye Q, Xu G, Lv D et al (2009) Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3\u03b2 (GSK-3\u03b2) inhibitors. Bioorganic Med Chem 17:4302\u20134312. https:\/\/doi.org\/10.1016\/j.bmc.2009.05.031","journal-title":"Bioorganic Med Chem"},{"key":"4032_CR71","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ejmech.2016.09.058","volume":"125","author":"I Khan","year":"2017","unstructured":"Khan I, Tantray MA, Alam MS, Hamid H (2017) Natural and synthetic bioactive inhibitors of glycogen synthase kinase. Eur J Med Chem 125:464\u2013477. https:\/\/doi.org\/10.1016\/j.ejmech.2016.09.058","journal-title":"Eur J Med Chem"},{"key":"4032_CR72","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1016\/j.bmcl.2013.03.119","volume":"23","author":"K Chun","year":"2013","unstructured":"Chun K, Park J-S, Lee H-C et al (2013) Synthesis and evaluation of 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives as glycogen synthase kinase-3 (GSK-3) inhibitors. Bioorg Med Chem Lett 23:3983\u20133987. https:\/\/doi.org\/10.1016\/j.bmcl.2013.03.119","journal-title":"Bioorg Med Chem Lett."},{"key":"4032_CR73","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.bmcl.2015.01.005","volume":"25","author":"K Fukunaga","year":"2015","unstructured":"Fukunaga K, Sakai D, Watanabe K et al (2015) Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3\u03b2 inhibitors for Alzheimer\u2019s disease. Bioorganic Med Chem Lett 25:1086\u20131091. https:\/\/doi.org\/10.1016\/j.bmcl.2015.01.005","journal-title":"Bioorganic Med Chem Lett"},{"key":"4032_CR74","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1747-0285.2010.01069.x","volume":"77","author":"N Zhang","year":"2011","unstructured":"Zhang N, Zhong R, Yan H, Jiang Y (2011) Structural features underlying selective inhibition of GSK3\u03b2 by Dibromocantharelline: implications for rational drug design. Chem Biol Drug Des 77:199\u2013205. https:\/\/doi.org\/10.1111\/j.1747-0285.2010.01069.x","journal-title":"Chem Biol Drug Des"},{"key":"4032_CR75","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1074-5521(00)00063-6","volume":"7","author":"L Meijer","year":"2000","unstructured":"Meijer L, Thunnissen AMWH, White AW et al (2000) Inhibition of cyclin-dependent kinases, GSK-3\u03b2 and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 7:51\u201363. https:\/\/doi.org\/10.1016\/S1074-5521(00)00063-6","journal-title":"Chem Biol"},{"key":"4032_CR76","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1016\/j.bmcl.2017.06.078","volume":"27","author":"Y Usui","year":"2017","unstructured":"Usui Y, Uehara F, Hiki S et al (2017) Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3\u03b2 inhibitors. Bioorganic Med Chem Lett 27:3726\u20133732. https:\/\/doi.org\/10.1016\/j.bmcl.2017.06.078","journal-title":"Bioorganic Med Chem Lett"},{"key":"4032_CR77","doi-asserted-by":"publisher","first-page":"5669","DOI":"10.1016\/j.bmcl.2016.10.060","volume":"26","author":"J Kim","year":"2016","unstructured":"Kim J, Moon Y, Hong S (2016) Identification of lead small molecule inhibitors of glycogen synthase kinase-3 beta using a fragment-linking strategy. Bioorganic Med Chem Lett 26:5669\u20135673. https:\/\/doi.org\/10.1016\/j.bmcl.2016.10.060","journal-title":"Bioorganic Med Chem Lett"},{"key":"4032_CR78","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.bmcl.2008.01.113","volume":"18","author":"Y Miyazaki","year":"2008","unstructured":"Miyazaki Y, Maeda Y, Sato H et al (2008) Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors. Bioorganic Med Chem Lett 18:1967\u20131971. https:\/\/doi.org\/10.1016\/j.bmcl.2008.01.113","journal-title":"Bioorganic Med Chem Lett"},{"key":"4032_CR79","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ejmech.2016.11.003","volume":"126","author":"M Mur\u00e1r","year":"2017","unstructured":"Mur\u00e1r M, Dobia\u0161 J, \u0160ramel P et al (2017) Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - a possible way to dual VEGFR2 TK\/CLK ligands. Eur J Med Chem 126:754\u2013761. https:\/\/doi.org\/10.1016\/j.ejmech.2016.11.003","journal-title":"Eur J Med Chem"},{"key":"4032_CR80","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1016\/j.bmcl.2014.09.017","volume":"24","author":"A Bruel","year":"2014","unstructured":"Bruel A, B\u00e9n\u00e9teau R, Chabanne M et al (2014) Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors. Bioorganic Med Chem Lett 24:5037\u20135040. https:\/\/doi.org\/10.1016\/j.bmcl.2014.09.017","journal-title":"Bioorganic Med Chem Lett"},{"key":"4032_CR81","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ejmech.2014.04.055","volume":"80","author":"O Dehbi","year":"2014","unstructured":"Dehbi O, Tikad A, Bourg S et al (2014) Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted Pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors. Eur J Med Chem 80:352\u2013363. https:\/\/doi.org\/10.1016\/j.ejmech.2014.04.055","journal-title":"Eur J Med Chem"},{"key":"4032_CR82","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ejmech.2015.06.046","volume":"101","author":"R Boulahjar","year":"2015","unstructured":"Boulahjar R, Ouach A, Bourg S et al (2015) Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors. Eur J Med Chem 101:274\u2013287. https:\/\/doi.org\/10.1016\/j.ejmech.2015.06.046","journal-title":"Eur J Med Chem"},{"key":"4032_CR83","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejmech.2012.10.006","volume":"58","author":"Y Loidreau","year":"2012","unstructured":"Loidreau Y, Marchand P, Dubouilh-Benard C et al (2012) Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d] pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser\/Thr kinase inhibitors. Eur J Med Chem 58:171\u2013183. https:\/\/doi.org\/10.1016\/j.ejmech.2012.10.006","journal-title":"Eur J Med Chem"},{"key":"4032_CR84","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ejmech.2012.11.030","volume":"59","author":"Y Loidreau","year":"2013","unstructured":"Loidreau Y, Marchand P, Dubouilh-Benard C et al (2013) Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d] pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases. Eur J Med Chem 59:283\u2013295. https:\/\/doi.org\/10.1016\/j.ejmech.2012.11.030","journal-title":"Eur J Med Chem"},{"key":"4032_CR85","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bmcl.2012.10.141","volume":"23","author":"L Demange","year":"2013","unstructured":"Demange L, Abdellah FN, Lozach O et al (2013) Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling. Bioorganic Med Chem Lett 23:125\u2013131. https:\/\/doi.org\/10.1016\/j.bmcl.2012.10.141","journal-title":"Bioorganic Med Chem Lett"},{"key":"4032_CR86","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1021\/ci400115b","volume":"53","author":"MR Bauer","year":"2013","unstructured":"Bauer MR, Ibrahim TM, Vogel SM, Boeckler FM (2013) Evaluation and optimization of virtual screening workflows with DEKOIS 2.0 - a public library of challenging docking benchmark sets. J Chem Inf Model 53:1447\u20131462. https:\/\/doi.org\/10.1021\/ci400115b","journal-title":"J Chem Inf Model"},{"key":"4032_CR87","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/nar\/gks378","volume":"40","author":"DR Koes","year":"2012","unstructured":"Koes DR, Camacho CJ (2012) ZINCPharmer: pharmacophore search of the ZINC database. Nucleic Acids Res 40:409\u2013414. https:\/\/doi.org\/10.1093\/nar\/gks378","journal-title":"Nucleic Acids Res."},{"key":"4032_CR88","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1021\/jm040835a","volume":"48","author":"J Kazius","year":"2005","unstructured":"Kazius J, McGuire R, Bursi R (2005) Derivation and validation of toxicophores for mutagenicity prediction. J Med Chem 48:312\u2013320. https:\/\/doi.org\/10.1021\/jm040835a","journal-title":"J Med Chem"},{"key":"4032_CR89","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1023\/A:1008130001697","volume":"14","author":"TI Opera","year":"2000","unstructured":"Opera TI (2000) Property distribution of drug-related chemical databases. J Comput Aided Mol Des 14:251\u2013264","journal-title":"J Comput Aided Mol Des."},{"key":"4032_CR90","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","volume":"2","author":"H Pajouhesh","year":"2005","unstructured":"Pajouhesh H, Lenz GR (2005) Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2:541\u2013553. https:\/\/doi.org\/10.1602\/neurorx.2.4.541","journal-title":"NeuroRx"},{"key":"4032_CR91","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1021\/jm901137j","volume":"53","author":"JB Baell","year":"2010","unstructured":"Baell JB, Holloway GA (2010) New substructure filters for removal of Pan assay interference compounds ( PAINS ) from screening libraries and for their exclusion in bioassays. J Med Chem 53:2719\u20132740. https:\/\/doi.org\/10.1021\/jm901137j","journal-title":"J Med Chem"},{"key":"4032_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13321-017-0213-3","volume":"9","author":"T Sch\u00e4fer","year":"2017","unstructured":"Sch\u00e4fer T, Kriege N, Humbeck L et al (2017) Scaffold hunter\u00a0: a comprehensive visual analytics framework for drug discovery. J Cheminform 9:1\u201318. https:\/\/doi.org\/10.1186\/s13321-017-0213-3","journal-title":"J Cheminform"},{"key":"4032_CR93","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/cmdc.201600182","volume":"11","author":"A Daina","year":"2016","unstructured":"Daina A, Zoete V (2016) A BOILED-egg to predict gastrointestinal absorption and brain penetration of Small molecules. ChemMedChem 11:1117\u20131121. https:\/\/doi.org\/10.1002\/cmdc.201600182","journal-title":"ChemMedChem"},{"key":"4032_CR94","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1021\/ci500467k","volume":"54","author":"A Daina","year":"2014","unstructured":"Daina A, Michielin O, Zoete V (2014) ILOGP: a simple, robust, and efficient description of n-octanol\/water partition coefficient for drug design using the GB\/SA approach. J Chem Inf Model 54:3284\u20133301. https:\/\/doi.org\/10.1021\/ci500467k","journal-title":"J. Chem Inf Model."},{"key":"4032_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME\u00a0: a free web tool to evaluate pharmacokinetics , drug- likeness and medicinal chemistry friendliness of small molecules. Nat Publ Gr 7:1\u201313. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Nat Publ Gr"},{"key":"4032_CR96","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/ci600338x","volume":"47","author":"A Schuffenhauer","year":"2007","unstructured":"Schuffenhauer A, Ertl P, Roggo S et al (2007) The scaffold tree - visualization of the scaffold universe by hierarchical scaffold classification. J Chem Inf Model 47:47\u201358. https:\/\/doi.org\/10.1021\/ci600338x","journal-title":"J Chem Inf Model"}],"container-title":["Journal of Molecular Modeling"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-019-4032-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00894-019-4032-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-019-4032-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T12:52:20Z","timestamp":1663505540000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00894-019-4032-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,25]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4032"],"URL":"https:\/\/doi.org\/10.1007\/s00894-019-4032-5","relation":{},"ISSN":["1610-2940","0948-5023"],"issn-type":[{"value":"1610-2940","type":"print"},{"value":"0948-5023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,25]]},"assertion":[{"value":"3 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"171"}}